BACKGROUND: Numerous patients will develop recurrent disease after esophagectomy for esophageal carcinoma (EC). In literature, survival after recurrent EC is poor with 6-8 months. In these studies, diagnostic imaging during follow-up (FU) is routinely performed. In the Netherlands, routine imaging is not part of FU and only performed on indication. The aim of this study was to determine survival after diagnosis of recurrent disease in patients after esophagectomy without routine imaging during FU. METHODS: All EC patients who underwent esophagectomy between 1993 and 2010 were included and followed for clinical evidence of recurrent EC. Location, symptoms, diagnosis, and treatment of recurrent disease were registered. Pattern of recurrence was compared between patients who underwent neoadjuvant therapy and patients who underwent surgery alone. Survival after detection of recurrence was determined in all patients and related to the year of surgery. RESULTS: A total of 493 of 1,088 patients (45 %) who underwent esophagectomy between 1993 and 2010 developed recurrent disease. Median interval between esophagectomy and recurrence was 10.5 months. Within the first 2 years after surgery, 33 % of patients developed recurrent EC. The majority of patients (51 %) were diagnosed with distant metastases. Locoregional recurrence occurred significantly less often among patients who underwent neoadjuvant therapy (6 vs 16 %, p = .017). Median survival after diagnosis of recurrent disease was 3 months. No relation was observed between the year of surgery and survival after recurrent disease (p = .931). CONCLUSIONS: Survival after recurrent EC in patients who undergo FU without routine imaging after esophagectomy is approximately 3 months and has not improved over the past 18 years.
BACKGROUND: Numerous patients will develop recurrent disease after esophagectomy for esophageal carcinoma (EC). In literature, survival after recurrent EC is poor with 6-8 months. In these studies, diagnostic imaging during follow-up (FU) is routinely performed. In the Netherlands, routine imaging is not part of FU and only performed on indication. The aim of this study was to determine survival after diagnosis of recurrent disease in patients after esophagectomy without routine imaging during FU. METHODS: All EC patients who underwent esophagectomy between 1993 and 2010 were included and followed for clinical evidence of recurrent EC. Location, symptoms, diagnosis, and treatment of recurrent disease were registered. Pattern of recurrence was compared between patients who underwent neoadjuvant therapy and patients who underwent surgery alone. Survival after detection of recurrence was determined in all patients and related to the year of surgery. RESULTS: A total of 493 of 1,088 patients (45 %) who underwent esophagectomy between 1993 and 2010 developed recurrent disease. Median interval between esophagectomy and recurrence was 10.5 months. Within the first 2 years after surgery, 33 % of patients developed recurrent EC. The majority of patients (51 %) were diagnosed with distant metastases. Locoregional recurrence occurred significantly less often among patients who underwent neoadjuvant therapy (6 vs 16 %, p = .017). Median survival after diagnosis of recurrent disease was 3 months. No relation was observed between the year of surgery and survival after recurrent disease (p = .931). CONCLUSIONS: Survival after recurrent EC in patients who undergo FU without routine imaging after esophagectomy is approximately 3 months and has not improved over the past 18 years.
Authors: Sonia L Betancourt Cuellar; Diana P Palacio; Carol C Wu; Brett W Carter; Arlene M Correa; Wayne L Hofstetter; Edith M Marom Journal: Br J Radiol Date: 2017-11-28 Impact factor: 3.039
Authors: Peter S N van Rossum; Nadia Haj Mohammad; Frank P Vleggaar; Richard van Hillegersberg Journal: Nat Rev Gastroenterol Hepatol Date: 2017-12-13 Impact factor: 46.802
Authors: Grace Gar-Lee Yue; Julia Kin-Ming Lee; Lin Li; Kar-Man Chan; Eric Chun-Wai Wong; Judy Yuet-Wah Chan; Kwok-Pui Fung; Vivian Wai Yan Lui; Philip Wai-Yan Chiu; Clara Bik-San Lau Journal: Am J Cancer Res Date: 2015-11-15 Impact factor: 6.166
Authors: Zhenxu Liu; Yi Lu; Ying Pu; Jun Liu; Bo Liu; Bo Yu; Ke Chen; Ting Fu; Chaoyong James Yang; Huixia Liu; Weihong Tan Journal: Sci Rep Date: 2015-12-21 Impact factor: 4.379
Authors: E Visser; A G Leeftink; P S N van Rossum; S Siesling; R van Hillegersberg; J P Ruurda Journal: Ann Surg Oncol Date: 2016-03-24 Impact factor: 5.344
Authors: K Parry; E Visser; P S N van Rossum; N Haj Mohammad; J P Ruurda; R van Hillegersberg Journal: Ann Surg Oncol Date: 2015-09-03 Impact factor: 5.344